Organic Active Ingredients TRIZ Cases

Mesothelin-binding antibodies use cleavable eribulin linkers to kill cancer cells while limiting toxicity to normal tissues.

Controlled chlorination and solvent precipitation improve purity and yield of a URAT1 inhibitor while easing separation for safer uric acid lowering.

A torus-like DNA mazzocchio uses modular linkers and fewer oligonucleotides to encapsulate diverse cargos with stable, biocompatible delivery.

A buffered epinephrine formulation with metabisulfite and EDTA limits oxidation and impurities, preserving potency during long-term storage.

Selective Helios degraders tune substituent patterns to improve IKZF2 degradation, metabolic stability, and reduced off-target effects.

Antibody-drug conjugates link anti-influenza antibodies with VX-787 or baloxavir payloads to broadly neutralize influenza A subtypes.

A phosphorus-containing SOS1 inhibitor uses a quinazoline-phosphonic acid scaffold to block RAS activation and ERK phosphorylation.

Galacto- and fructo-oligosaccharides directly suppress nasal epithelial chemokines to treat underlying non-allergic rhinitis inflammation.

Fluorinated cationic lipids in lipid nanoparticles protect nucleic acids from plasma degradation while improving intracellular delivery and tolerability.

Gapmer oligonucleotides target human SNHG14 RNA to restore paternal UBE3A in neurons while limiting effects on SNORD115 and SNRPN.

A chimpanzee adenovirus vector delivers patient-specific tumor neoantigens while avoiding pre-existing human vector immunity and improving immune targeting.

Antibody-conjugated cyclic dinucleotides resist degradation and deliver stronger, targeted STING activation for anti-tumor and immune response.

Small molecules bind the WASp WH1 domain to block degradation, restore immune cell function, and avoid transplant and gene therapy risks.

An anti-CD37 antibody-drug conjugate paired with R-CHOP, R-CHP, alkylating, or immunomodulatory drugs improves combination efficacy in resistant B-cell cancers.

Enteric-coated losartan mini-tablets replace unstable pediatric suspensions with precise dosing, better swallowability, and bitter taste masking.

Engineered u-PA variants selectively cleave complement C3 to inhibit complement activation while reducing activity on plasminogen.

Engineered guide RNAs recruit endogenous ADAR to edit target RNA precisely, avoiding exogenous protein delivery and immunogenicity risks.

Selective CYP11A1 inhibitors block steroid hormone synthesis to suppress hormone-refractory prostate tumor growth with fewer side effects.

Novel evenamide hydrochloride crystal forms balance solubility with moisture stability, enabling pure, non-hygroscopic pharmaceutical formulations.

Antigen-primed dendritic cells combined with IFN-α and TLR agonists boost T-cell polarization and CD8+ CTL activation near diseased tissue.

A citrate crystal form improves stability, solubility, and bioavailability while lowering hygroscopicity for 5-HT2-targeted antipsychotic use.

Controlled 0.5-10 μm inhaled magnesium isoglycyrrhizinate improves pulmonary deposition, bioavailability, and side-effect profile.

A stable peptide inhibits hyaluronidase and reactive oxygen species to extend hyaluronic acid filler duration while supporting skin cell activation.

Local delivery of a pro-chondrogenic osteoarthritis compound relieves joint pain and slows cartilage degeneration with fewer systemic side effects.

Topical phentolamine constricts the pupil to improve near and far vision in presbyopia and mydriasis with once-daily dosing.

Ginkgo biloba terpene lactone compositions address the lack of tremor therapies, improving essential and vascular tremor without adverse reactions.

Novel naphthyridine MEK inhibitors are tuned to cross the blood-brain and blood-CSF barriers while maintaining CNS tumor treatment efficacy.

Phenolic glycolipid derivatives improve Mincle activation to boost TNF, INF-γ, and antibody responses with lower toxicity risk.

Small-molecule PD-L1 inhibitors block PD-1 signaling to boost immune response in HCC and help inhibit HBV and HDV replication.

A nanocrystalline darolutamide form raises solubility eightfold and improves bioavailability, enabling lower doses with stable solid-state properties.

Targeting ERβ expression or ERβ-TP53 binding creates a receptor-based treatment route for triple-negative breast cancer cells.

A quinoline derivative approach for advanced nasopharyngeal carcinoma that reduces tumor size and metastasis after prior chemo or radiotherapy.

Semi-saturated bicyclic compounds tune drug-like properties while inhibiting DNA polymerase Θ to improve treatment options for HR-deficient tumors.

A PRP-based composition boosts bone marrow endogenous cell proliferation to improve musculoskeletal repair, joint function, pain, and motion.

Screened parent lines and doubled haploid breeding raise S-methylmethionine in Brassica oleracea to improve nutritional value.

Novel covalent IDH1 and IDH2 mutant inhibitors improve selectivity and activity to lower D-2HG and support treatment of IDH-driven tumors.

Mobilizing bone marrow cells into peripheral blood enables apheresis-based HSC collection from deceased donors with less contamination and body disruption.

Methionine acts as a sacrificial antioxidant in aqueous insulin formulations, limiting oxidation, haze, and protein aggregation over time.

ATM inhibition activates cGAS/STING to boost T-cell infiltration and improve immune checkpoint therapy across more cancer patients.

Lyophilized pooled fetal support tissue preserves HC-HA/PTX3 and other bioactive factors, improving product uniformity and potency.

Amorphous dasatinib dispersions with polymers maintain drug delivery despite acid-reducing agents and elevated gastric pH, reducing PK variability.

A stable aqueous IV nicotinamide riboside formulation raises cellular NAD+ while minimizing pain, inflammation, and discomfort.

DCAF15-recruiting sulfonamides selectively degrade RRM proteins to target RNA splicing in cancer while reducing off-target toxicity.

Alternative bumetanide delivery through nasal, sublingual, or subcutaneous routes restores diuresis when oral absorption fails.

Fixed antibiotic dosing in overweight and obese patients avoids unreliable weight-based calculations, lowering toxicity while maintaining cure rates.

STRO-1+ multipotential cells are delivered to degenerate intervertebral discs to restore disc height and improve disc health markers.

Using R-ketamine without S-ketamine preserves rapid, sustained antidepressant effects while reducing psychotomimetic side effects.

Blocking IL-31 or JAK interrupts the itch pathway triggered by FXR agonists, helping preserve liver therapy while reducing pruritus.

Specific oral testosterone dosing, alone or with d-alpha tocopherol, improves NASH liver fat, inflammation, and fibrosis with minimal adverse effects.

Biomarker-guided ANAVEX2-73 dosing helps relieve Rett syndrome symptoms while limiting adverse events and easing administration.

Salt formation and controlled crystallization improve the stability and pharmaceutical usability of a naphthyridine amide compound for clinical use.

A probiotic-prebiotic blend with hyaluronic acid helps rebalance gut flora while strengthening intestinal barrier function and hydration.

Chiral imidazopiperazine compounds improve selective CBP/P300 bromodomain inhibition to modulate gene expression in proliferative disease.

Combining a thioether-linked anti-CDH6 ADC with a VEGF inhibitor boosts tumor suppression while maintaining a safe treatment profile.

Alkalinizing agents raise GI pH to speed pitolisant or doxepin absorption, shortening Tmax and increasing peak plasma exposure.

A new sulfonamide class is paired with taxanes or vinca alkaloids to improve cancer treatment and help reduce recurrence risk.

Altered stable isotope ratios with deuterium-depleted water suppress degeneration by influencing cellular function, DNA repair, and protein synthesis.

Pre-formulated hydromorphone in buffered sodium chloride IV bags avoids compounding errors and maintains sterility and stability for room-temperature storage.

Timed short-acting CDK4/6 inhibitor dosing shields immune cells during chemotherapy, improving checkpoint inhibitor response and durable antitumor immunity.

A hot-melt extruded copolymer matrix enables humidity-resistant, pH-independent pyridostigmine release with strength and bioequivalent sustained delivery.

Timed oral edaravone dosing after high-fat, standard, or light meals stabilizes absorption and drug levels for more consistent treatment.

ABCG2 inhibition reduces PPIX efflux to limit skin and liver exposure, helping treat phototoxicity and hepatotoxicity in EPP and XLP.

Modulating U1 snRNP protects nascent transcripts from premature polyadenylation, reshaping mRNA isoforms and oncogenicity.

Capsid-binding compounds crosslink conserved viral proteins to block particle release and deliver broad RNA virus activity with low cytotoxicity.

Bifunctional compounds recruit IRAK4 to VHL, CRBN, or IAP ligases to drive ubiquitination and proteasomal degradation for disease treatment.

Using basic pH above 7, this case improves lipoxin A4 mimetic yield and stability while reducing synthesis and stabilization cost.

Modified oligonucleotides bind PMP22 transcripts to lower expression, helping relieve Charcot-Marie-Tooth disease symptoms.

ASOs raise SynGAP protein by blocking miRNA interference, easing 5′-UTR repression, and depleting antisense lncRNAs.

Crystalline polymorphs of an SHP2 inhibitor improve therapeutic effectiveness while enabling solid-form selection for stability and manufacturing.

A stable crystalline Form 2 replaces the hygroscopic amorphous solid, enabling ambient storage and easier pharmaceutical handling.

Bioreducible polymer particles and gels enable stable peptide or siRNA delivery with tunable release through hydrolysis, enzymes, and disulfide reduction.

Microfluidic mixing and solvent removal enable scalable RNA liposome production with controlled size, high encapsulation efficiency, and preserved activity.

Prodrug modification improves solubility, stability, and bioavailability of Tyk2 modulators for broader dosing and formulation in autoimmune therapy.

Novel aldose reductase inhibitors are tuned to cross the blood-brain barrier and reduce ROS-driven infarct damage in ischemic stroke.

Crystalline and amorphous Bcl-2/Bcl-xL inhibitor forms use controlled crystallization to improve solubility, stability, and bioavailability.

Controlled Form VI crystallization improves maribavir synthesis yield to at least 45% while lowering impurities for oral formulations.

Oxygenated phosphonic acid derivatives inhibit PI3K/Akt to suppress inflammation and mast cell degranulation with low cytotoxicity.

Targeted DUX4-binding polynucleic acid conjugates improve RNAi uptake and stability while reducing immune stimulation in FSHD treatment.

BRD9-targeting compounds reduce BRD9 levels and activity to treat BAF-related cancers and infections with one therapeutic mechanism.

A self-emulsifying abiraterone acetate composition forms an O/W nanoemulsion in the gut to raise oral absorption and reduce food-related variability.

Cyclic IL-22 dimer therapy targets gut epithelial recovery in GvHD while limiting the immune-function tradeoff of standard immunosuppression.

By blocking MAST1, MEK activation, and HSP90 support, this combination therapy restores platinum drug sensitivity in resistant cancer cells.

Chk1 inhibitor compounds block cell cycle checkpoints and DNA repair, boosting DNA-damaging cancer therapy while preserving treatment selectivity.

A PPARα-agonist compound lowers blood LDL-C when statins fall short or cause side effects, expanding treatment options for hypercholesterolemia.

Broad-spectrum Formula I compounds inhibit multiple KRas mutations and help bypass resistance seen with existing KRas G12C inhibitors.

An HPMC-AS rifaximin solid dispersion improves cirrhosis treatment by reducing hospitalization time, mortality, and refractory ascites.

Selective norepinephrine inhibition with reboxetine reduces cataplexy attacks and improves sleep quality without DEA scheduling burdens.

A transcription factor composition restores cellular viability and epigenetic function while avoiding c-Myc-related safety risks and teratoma formation.

Specific β1-3 Gal-Gal oligosaccharide ratios reduce branched short-chain fatty acids while supporting gut microbiota health in high-protein diets.

By inhibiting PHD-mediated HIF hydroxylation, these compounds boost erythropoietin synthesis and iron metabolism to improve anemia treatment.

Isolated CTGF and TGFβ1 replace heterogeneous NCCM to restore disc matrix, reduce pain, and promote regenerative repair.

A four-drug ACT regimen combines sublingual artemether, artesunate, berberine, and primaquine to overcome resistance and prevent malaria relapse.

Purified S. epidermidis lipoteichoic acid modulates TLR2-linked immune pathways to reduce tactile allodynia and inflammation in CPPS and arthritis.

Single-step resorbable nonwoven implant pouches enable tissue ingrowth and antibiotic elution while avoiding bacteria-trapping multifilament fabrics.

Sarmentosin esters reversibly inhibit MAO-A and MAO-B to modulate neurotransmitters while avoiding the side effects of irreversible MAO inhibitors.

A hyaluronic acid ester hydrogel carries zinc gluconate in soluble form, improving residence time and viscoelasticity for topical and injectable use.

Carbon-coated biocompatible nanospheres stabilize single-strand RNA at 0°C to 25°C, preserving integrity during storage and transport.

An anti-transferrin receptor RNA conjugate improves cellular uptake, blood stability, and DMPK silencing for DM1 treatment.

A lenacapavir free-acid formulation with PEG 300, water, and ethanol enables once-yearly HIV PrEP to improve adherence and access.

Defined benzene-ring substitutions expand PI3K inhibitor structures to improve cancer treatment selectivity while reducing toxic side effects.

NBMI binds toxic NAPQI and inhibits TRPA1 to address paracetamol toxicity beyond the usual 8-hour treatment window.

Gemcitabine–cisplatin offers limited response and may face resistance in cholangiocarcinoma; anti-Claudin-1 antibodies target overexpressed Claudin-1.

TIPS protection helps 3′-hydroxyl nucleoside monomers withstand deprotection, improving oligonucleotide yield and purity.

Learn how DHMBA reduces jejunal MDA and 8-OHdG while increasing ZIP4 and serum zinc under low-zinc dietary conditions.

Copper-chelators pair with MAPK inhibitors to induce ROS, increase cancer-cell sensitivity, and address resistance and heterogeneity.

Conventional protein assays are limited by biological variance; exon-skipped mRNA internal controls support precise therapeutic dose adjustment.

Conventional kidney treatments may leave proteinuria elevated; dual angiotensin and endothelin receptor blockade targets UP/C reduction.

Metal controls and protease screening help produce collagenase compositions above 95% RP-HPLC purity with improved stability.

Combining cannabis and Hericium erinaceus extracts in a beverage targets SUD withdrawal symptoms and addictive behaviors through complementary pathways.

Systematic molecular changes give phthalazine PK modulators improved ADME profiles while restoring cellular pyruvate kinase activity.

Current renal disease treatments lack effective extracellular-vesicle options; hypoxic renal-cell culture alters vesicle miRNAs and proteins for tissue regeneration.

A base reaction under inert conditions converts amphetamine carbamate into carbonate ions, enabling ion chromatography to measure low levels in transdermal compositions.

Replacing the conventional ketone protecting group with a 1,5-dioxa ketal helps deplete impurities and stabilize Sonrotoclax intermediates.

Tumor microenvironment heterogeneity limits checkpoint therapy; hydroxyprogesterone caproate increases TIL and CD8+ T-cell infiltration to strengthen tumor suppression.

Transient vasoconstrictors provide limited relief, while a 0.25% lapachol moisturizer reduced facial erythema by 29% after eight weeks.

Frequent injections and systemic toxicity challenge macular edema treatment; a biodegradable implant sustains local corticosteroid release in the eye.

Chemical structure changes tune CD73 inhibition and metabolic stability for compounds intended for cancer and immune-related therapies.

Combining bovine milk exosomes with vitamin K2 targets weak osteoblast differentiation to support bone formation and homeostasis.

Learn how SARM1-modulating compounds inhibit NADase activity to prevent axonal degeneration in neurodegenerative disease.

Current NRTI regimens suppress HBV replication but leave cccDNA and immune control unresolved; this therapy combines an anti-HBV antibody, siRNA, and NRTI action.

Novel compounds use cereblon E3 ligase activity to induce substrate degradation, aiming for stronger efficacy with reduced toxicity.

External HPMCAS stabilizes amorphous drug dispersions against storage recrystallization while preserving high initial dissolution rates.

Controlled synthesis and packaging keep ribociclib compositions low in nitrosamines while supporting shelf life without cold-chain storage.

MTA-bound selectivity directs PRMT5 inhibition toward MTAP-deleted tumors while limiting effects on normal tissues with intact MTAP.

Modified antisense oligonucleotides target Tau mRNA to reduce Tau protein levels and address neurodegeneration beyond symptom relief.

PS/PC liposomes containing lyso-PS complex therapeutic proteins to reduce antibody responses and induce immune tolerance.

Macropa-chelated actinium-225 antibodies target PSMA while limiting radionuclide dissociation and toxicity in healthy tissue.

Crosslinked polyacrylamide hydrogels bind damaged cartilage and exposed collagen, providing durable lubrication, a protective barrier, and sustained therapeutic release.

Non-progestin SHBG ligands displace bound progestin in plasma, increasing free hormone levels for smaller patches and fewer estrogen-related side effects.

Cyclodextrin inclusion complexes and acidic buffering help keep ready-to-use injectable DMT soluble, clear, and stable during storage.

Combining oxytocin peptide with magnesium ions enhances social communication, reduces anxiety, and extends treatment effects compared with oxytocin alone.

Controlled lactide and glycolide feed rates address non-uniform PLGA chains and improve drug release and loading behavior.

A standardized cream combines moisturizer components, corticosteroid, silymarin, and EGCG to limit skin damage during radiation therapy.

ASOs targeting ABCB11 promoter- and enhancer-associated RNAs raise gene expression to improve bile acid efflux in cholestasis.

To address antibiotic resistance and weak target-site delivery, a gel bacteriophage cocktail targets E. coli and S. aureus intramammarily.

See how a cyclobenzaprine HCl–mannitol eutectic uses transmucosal delivery for early symptom relief while limiting weight and blood-pressure changes.

Antioxidants protect cannabidiol from oxidation while biodegradable polymers support sustained release in uniform microparticles.

A 2–3 mg/kg sodium polynucleotide injection treats canine and feline arthritis while reducing pain, inflammation, and joint friction.

Physicochemical property challenges are addressed with prodrugs that hydrolyze in vivo to release active GPR52 modulators.

Variable crystalline forms can affect oxybutynin stability and efficacy; controlled crystallization creates Forms A–C with consistent pharmacokinetic properties.

Hydrolytic, oxidative, and reductive linkages help polymer particles preserve drug integrity during delivery and release agents at targeted sites.

Novel oxysterol formulas tune oxidation sites and substituents to modulate NMDA receptors across CNS and metabolic disorders.

Existing therapies can leave TLR7/8/9-driven inflammation inadequately controlled; these compounds inhibit the pathways and modulate cytokine and B-cell activity.

Rapid metabolism and gastrointestinal absorption limits destabilize levodopa exposure; controlled release extends coverage and reduces Off time.

Mixing wet microalgae slurry with ethanol avoids toxic solvent residues and produces low-ash, omega-3-rich miscella.

Specific deuterium placement in HDAC inhibitors targets subtype selectivity and metabolic stability for stronger PD-1 and VEGF combination effects.

A synergistic blend of curcuma, coffee fruit extract, DHA, and phospholipids targets visual fatigue and supports visual function.

Mutant FGFR kinases can evade standard inhibitors; indazole sulfoximine compounds extend inhibition to wild-type and variant targets.

Compound A uses an oxygen-containing fatty acid structure to reduce hepatic fibrosis and inflammation in NASH and ASH.

An antioxidant-free aqueous norepinephrine buffer uses pH control and chelation to limit degradation and isomerization during storage.

A medical infusion pump delivers high-concentration insulin using a non-ionic surfactant to maintain solubility.

An NAE inhibitor blocks IL-2R desensitization, maintaining long-term efficacy of low-dose interleukin-2 therapy for autoimmune diseases.

Blocking the mitochondrial pyruvate carrier prevents terminal differentiation, enabling expanded T-cells to maintain persistence and anti-tumor activity.

Engineered AAV vectors incorporate n-mer capsid motifs to target CNS endothelial cells, overcoming low transduction efficiency in conventional viral systems.

A balloon catheter delivers photosensitizing agents directly to tumor tissue.

NEAT1 levels predict prostate cancer progression while interfering RNA molecules target the transcript to inhibit tumor growth.

Covalent binding of nitrogen heterocyclic inhibitor blocks mutant FLT3 activity, resolving drug resistance in acute myeloid leukemia.

Dissolving nobiletin with a water-soluble hesperidin derivative in ethanol aqueous solution creates an amorphous solid dispersion.

Solid dispersion formulation overcomes poor solubility of androgen receptor N-terminal domain inhibitor to treat castration-resistant prostate cancer.

Targeting MG29 expression resolves insulin resistance and glucose metabolism defects in skeletal muscle.

Klotho protein mediates tumor suppression by blocking IGF-1 receptors, resolving the trade-off between treatment efficacy and severe side effects.

ActRIIB-Fc fusion protein balances bone resorption and formation via periodic dosing to minimize side effects while increasing bone density.

A method selecting cancer patients for combination therapy using specific peripheral blood immune cell markers.

A transdermal patch delivers clobazam through the skin using permeation enhancers.

Inositol polyphosphates inhibit calciprotein particle maturation to stop pathological crystallization progression in chronic kidney disease.

Cross-linked hydrogel matrices disperse active ingredients to achieve high drug loading while a pH-dependent coating prevents premature release in the stomach.

Irreversible covalent bonding of tricyclic compounds sustains Bruton's tyrosine kinase occupancy at lower doses, reducing toxicity and off-target effects.

A fluid-jet mill recirculates drug-carrier mixtures to achieve mechanochemical activation and high amorphous phase content.

N-benzylaniline derivatives dissociate the nNOS-PSD-95 complex, reducing excessive nitric oxide without impairing NMDA receptors to treat cerebral ischemia.

Combines platelet enriched plasma with stem cell conditioned medium to promote angiogenesis and collagen synthesis in cutaneous wounds.

Inhaled halloysite nanotube and magnetic ferrite composite delivers dexamethasone to lungs, improving bioavailability while reducing systemic side effects.

Oral liquid celecoxib formulation prevents precipitation in gastric fluid by maintaining amorphous drug state, accelerating onset of action.

A ponesimod regimen reduces the rate of brain ventricular volume increase by 20 to 80 percent relative to standard care treatments.

Prenylated isoflavones inhibit P-glycoprotein to overcome multidrug resistance and restore chemotherapeutic efficacy.

A fibrous dosage form uses a three-dimensional structural network of drug-containing fibers to enable rapid and predictable immediate-release applications.

Modular synthesis of diverse indole derivatives resolves the trade-off between structural complexity and process manageability, enabling efficient SAR studies.

Formula I compounds selectively inhibit Factor IXa, resolving the trade-off between inhibition efficacy and specificity to treat thrombosis.

Aminothiophene compounds block calcium-activated chloride channels, reducing fluid secretion without antibiotic resistance.

Imidazo[1,2-b]pyridazine derivatives overcome limited dual inhibition by targeting both ROS1 and NTRK kinases simultaneously.

Segmenting the molecule allows independent optimization of antifungal and anti-angiogenic functions, reducing harmful side effects.

Ivermectin formulations with specific surfactants treat spasticity while reducing side effects from traditional medications.

A topical composition using pectin and Centella asiatica selectively inhibits pathogenic bacteria adhesion while preserving the natural skin flora balance.

Engineered Candida bombicola cells optimize sophorolipid production by balancing carbon yield against genetic modification complexity.

Merging PPARγ activation with Smad3 inhibition resolves insufficient brown adipose conversion by boosting UCP-1 levels and energy dissipation.

Baricitinib blocks JAK-mediated autoimmune pathways, resolving UDCA non-response in primary biliary cholangitis.

Inhibiting S100A9/S100A12 complex formation prevents cardiovascular calcification where current therapies fail.

Preselecting tumor-infiltrating lymphocytes via PD-1 and CD39 markers overcomes manufacturing bottlenecks by enriching for cytotoxic subsets.

Cancer-specific promoter DMP directs gene interference to inhibit iron export, overcoming homeostasis resistance and enabling reliable ferroptosis induction.

Modifying molecular parameters with fused aryl structures improves PRMT5 inhibition efficacy across malignancies.

Vacuum filling controls particle size distributions and densities to resolve content uniformity and flowability contradictions in dry powder inhalers.